|
SWI has identified two new exciting IPOs in BioTech
Los Angeles, CA. June 22, 2017. As part of our service to our subscribers, we frequently scrub the New Offerings market for promising IPOS that fit into our investing strategy. Here are two new candidates. To conveniently participate in these IPOs, we have provided you with links to the appropriate locations to download prospectus of the companies and conditions on how to participate in these IPOs via E*Trade.
|
|
|
|
|
Dova Pharmaceutical, Inc.
Last Filed Shares 4,062,500
Last Filed Price $15 - $17
|
|
|
|
DOVA is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Our drug candidate, avatrombopag, which we acquired from Eisai, Inc., or Eisai, in March 2016, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that we are developing for the treatment of thrombocytopenia. We have recently completed two identically designed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease, or CLD, undergoing non-emergent minimally to moderately invasive medical procedures. Avatrombopag met the primary and secondary endpoints in each of these clinical trials with high statistical significance. Based on these results, a new drug application, or NDA, is planned for submission
|
|
|
|
|
Aileron Therapeutics, Inc.
Last Filed Shares 3,7500,000
LAst filed Price $15 - $17
|
|
|
|
Aileron is a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Our lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2. Our ongoing clinical trials of ALRN-6924 consist of a Phase 1 trial for the treatment of advanced solid tumors or lymphomas, a Phase 2a trial for the treatment of peripheral T-cell lymphoma, or PTCL, a Phase 1 trial for the treatment of acute myeloid leukemia, or AML, and advanced myelodysplastic syndrome, or MDS, as a monotherapy and a Phase 1b trial for the treatment of AML/MDS in combination with cytosine arabinoside, or Ara-C.
To access and download the preliminary prospectus for the offering, please visit:
visit https://www.etrade.com/rtpublish/images/ALRN_Red.pdf. f
|
|
|
A separate registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.
To participate in an IPO through E*TRADE, you must be a customer of E*TRADE Securities LLC. For more information regarding the process for participating in public offerings through E*TRADE Securities and eligibility requirements, please visit https://us.etrade.com/e/t/ipo/newissuecenter?Message=NewIssueCenter:1
|
|
|
StockWatchIndex, SWI Research (SWI), Consulting for Strategic Growth and LaunchPad (LP) are not registered investment advisers and the information provided herein, or any other SWI/LP publication, are not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI/LP make no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications, or on their web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI/LP deems to be reliable third party entities, but SWI/LP does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. SWI/LP is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI/LP publication, or its web sites and are not obligated to update and/or correct information. No liability is accepted by SWI/LP whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI/LP expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice. Please visit
www.swiresearch.com/#!legal-ease/lmvw1
for a full text of our Disclaimer, Privacy policy and Terms of Use.
|
|
|
|
|
|
|
